ABL1 and acute lymphoblastic leukemia: BCR–ABL1 has been widely used as a biomarker and prognostic factor in patients with ALL [134], and its specific inhibitor, Glivec (imatinib), has been effectively used to target CML and ALL with BCR–ABL fusions [135].